Neoadjuvant chemotherapy plus trastuzumab in stage II/III breast cancer with low HER2 expression

被引：1
|
作者：
Khan, Qamar J.
O'Dea, Anne
Fabian, Carol J.
Connor, Carol Sue
McGinness, Marilee
Mammen, Joshua Matthew Varghise
Wagner, Jamie Lynn
Baccaray, Stella
Springer, Michelle
Yeh, Henry
Sharma, Priyanka
机构：
[1] Univ Kansas Med Ctr, Kansas City, KS USA
[2] Drieling Schmidt Canc Inst, Hays, KS USA
[3] Univ Kansas Med Ctr, Westwood, KS USA
[4] Univ Kansas, Kansas City, KS USA
[5] Univ Kansas, Olathe, KS USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.1039
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1039
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Complete response after "neoadjuvant" pertuzumab plus trastuzumab plus docetaxel chemotherapy in Her2-positive breast cancer
    Lai-Tiong, F.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (05) : 836 - 837
  • [42] Quantitative estrogen receptor expression affects pathologic complete response to neoadjuvant chemotherapy in patients with early-stage breast cancer with low expression of HER2
    Iwase, Toshiaki
    Fujii, Takeo
    Yam, Clinton
    Dong, Wenli
    Shen, Yu
    Tripathy, Debu
    Ueno, Naoto T.
    CANCER RESEARCH, 2023, 83 (05)
  • [43] HER2 Expression Impacts Trastuzumab Deruxtecan Efficacy in Breast Cancer
    不详
    CANCER DISCOVERY, 2023, 13 (10) : 2117 - 2117
  • [44] Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis
    Ruo-Xi Wang
    Sheng Chen
    Xi Jin
    Can-Ming Chen
    Zhi-Ming Shao
    Breast Cancer Research and Treatment, 2017, 161 : 259 - 267
  • [45] Trastuzumab plus gemcitabine and cisplatin chemotherapy for HER2/neu-overexpressing breast cancer with visceral metastasis
    Elsaid, A. A.
    Elkerm, Y.
    El-Shami, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [46] Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis
    Wang, Ruo-Xi
    Chen, Sheng
    Jin, Xi
    Chen, Can-Ming
    Shao, Zhi-Ming
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 161 (02) : 259 - 267
  • [47] TRUDI: A phase II study of neoadjuvant TRastuzumab derUxtecan and Durvalumab for stage III HER2expressing Inflammatory breast cancer
    Tarantino, Paolo
    Niman, Samuel
    Giordano, Antonio
    Nakhlis, Faina
    Bellon, Jennifer
    Woodward, Wendy
    Nasrazadani, Azadeh
    Saleem, Sadia
    Lucci, Anthony
    DeMeo, Michelle
    Ueno, Naoto
    Tolaney, Sara
    Valero, Vicente
    Regan, Meredith
    Layman, Rachel
    Lynce, Filipa
    CANCER RESEARCH, 2024, 84 (09)
  • [48] First line chemotherapy plus trastuzumab in metastatic breast cancer HER2 positive - Observational institutional study
    Aitelhaj, Meryem
    Lkhoyaali, Siham
    Rais, Ghizlane
    Boutayeb, Saber
    Errihani, Hassan
    PAN AFRICAN MEDICAL JOURNAL, 2016, 24
  • [49] Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer
    Wolff, Antonio C.
    Mcshane, Lisa M.
    Allison, Kimberly H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (08): : 829 - 831
  • [50] Neoadjuvant chemotherapy in stage III breast cancer
    Alassas, M
    Chu, QY
    Burton, G
    Ampil, F
    Mizell, J
    Li, BD
    AMERICAN SURGEON, 2005, 71 (06) : 487 - 492
12345